167 related articles for article (PubMed ID: 32556117)
1. STAT3 and AKT signaling pathways mediate oncogenic role of NRSF in hepatocellular carcinoma.
Ma M; Zhou Y; Sun R; Shi J; Tan Y; Yang H; Zhang M; Shen R; Xu L; Wang Z; Fei J
Acta Biochim Biophys Sin (Shanghai); 2020 Oct; 52(10):1063-1070. PubMed ID: 32556117
[TBL] [Abstract][Full Text] [Related]
2. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
3. Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways.
Cheng J; Zhong Y; Chen S; Sun Y; Huang L; Kang Y; Chen B; Chen G; Wang F; Tian Y; Liu W; Feng GS; Lu Z
FASEB J; 2017 Dec; 31(12):5530-5542. PubMed ID: 28842424
[TBL] [Abstract][Full Text] [Related]
4. DJ-1 promotes development of DEN-induced hepatocellular carcinoma and proliferation of liver cancer cells.
Qiu B; Wang J; Yu Y; Zhen C; Gu J; Liu W; Wen Y; Chen L; Gao Y; Xia Q; Kong X
Oncotarget; 2017 Jan; 8(5):8499-8511. PubMed ID: 28036277
[TBL] [Abstract][Full Text] [Related]
5. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
[TBL] [Abstract][Full Text] [Related]
6. β-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling.
Yang Y; Guo Y; Tan S; Ke B; Tao J; Liu H; Jiang J; Chen J; Chen G; Wu B
Nat Commun; 2015 Jun; 6():7369. PubMed ID: 26077142
[TBL] [Abstract][Full Text] [Related]
7. Role of insulin receptor substrates in the progression of hepatocellular carcinoma.
Sakurai Y; Kubota N; Takamoto I; Obata A; Iwamoto M; Hayashi T; Aihara M; Kubota T; Nishihara H; Kadowaki T
Sci Rep; 2017 Jul; 7(1):5387. PubMed ID: 28710407
[TBL] [Abstract][Full Text] [Related]
8. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
9. Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
Mello T; Materozzi M; Zanieri F; Simeone I; Ceni E; Bereshchenko O; Polvani S; Tarocchi M; Marroncini G; Nerlov C; Guasti D; Bani D; Pinzani M; Galli A
Int J Cancer; 2020 Jun; 146(12):3410-3422. PubMed ID: 31721195
[TBL] [Abstract][Full Text] [Related]
10. Abberent expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma.
Chen S; Zheng P; Wang W; Yi M; Chen P; Cai J; Li J; Peng Q; Ban Y; Zhou Y; Zeng Z; Li X; Xiong W; Li G; Xiang B
J Cell Physiol; 2018 Jun; 233(6):5002-5013. PubMed ID: 29227538
[TBL] [Abstract][Full Text] [Related]
11. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
12. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
[TBL] [Abstract][Full Text] [Related]
15. LncRNA DCST1-AS1 accelerates the proliferation, metastasis and autophagy of hepatocellular carcinoma cell by AKT/mTOR signaling pathways.
Li J; Zhai DS; Huang Q; Chen HL; Zhang Z; Tan QF
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6091-6104. PubMed ID: 31364110
[TBL] [Abstract][Full Text] [Related]
16. Loss of suppressors of cytokine signaling 3 promotes aggressiveness in hepatocellular carcinoma.
Wu WY; Kim H; Zhang CL; Meng XL; Wu ZS
J Invest Surg; 2014 Aug; 27(4):197-204. PubMed ID: 24476004
[TBL] [Abstract][Full Text] [Related]
17. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
Huang B; Huang M; Li Q
Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
[TBL] [Abstract][Full Text] [Related]
18. The long noncoding RNA NEAT1 contributes to hepatocellular carcinoma development by sponging miR-485 and enhancing the expression of the STAT3.
Zhang XN; Zhou J; Lu XJ
J Cell Physiol; 2018 Sep; 233(9):6733-6741. PubMed ID: 29219178
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway.
Wang X; Dong K; Jin Q; Ma Y; Yin S; Wang S
J Cell Biochem; 2019 Apr; 120(4):6781-6788. PubMed ID: 30382631
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
